Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Nivolumab Neoadjuvant NSCLC
NCT06667154Phase 2Recruiting
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in non-small cell lung cancer (NSCLC). Started Oct 2023; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06667154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06667154.